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Available online 6 March 2008NDRG4 is a novel member of the NDRG family (N-myc downstream-regulated gene). The roles of NDRG4 in
development have not previously been evaluated. We show that, during zebraﬁsh embryonic development,
ndrg4 is expressed exclusively in the embryonic heart, the central nervous system (CNS) and the sensory
system. Ndrg4 knockdown in zebraﬁsh embryos causes a marked reduction in proliferative myocytes and
results in hypoplastic hearts. This growth defect is associated with cardiac phenotypes in morphogenesis and
function, including abnormal heart looping, inefﬁcient circulation and weak contractility. We reveal that
ndrg4 is required for restricting the expression of versican and bmp4 to the developing atrioventricular
canal. This constellation of ndrg4 cardiac defects phenocopies those seen in mutant hearts of heartstrings (hst),
the tbx5 loss-of-function mutants in zebraﬁsh. We further show that ndrg4 expression is signiﬁcantly
decreased in hearts with reduced tbx5 activities. Conversely, increased expression of tbx5 that is due to tbx20
knockdown leads to an increase in ndrg4 expression. Together, our studies reveal an essential role of ndrg4 in
regulating proliferation and growth of cardiomyocytes, suggesting that ndrg4 may function downstream of
tbx5 during heart development and growth.
© 2008 Elsevier Inc. All rights reserved.Keywords:
Zebraﬁsh
ndrg4
Cardiogenesis
Myocardium
tbx5
tbx20Introduction
NDRG4 belongs to the differentiation-related NDRG family, which
includes four related members: NDRG1–4 (Qu et al., 2002; Zhou et al.,
2001). NDRG1 was ﬁrst isolated as a gene up-regulated in N-myc
mutant mouse embryos and repressed by N-myc and C-myc (Shimono
et al., 1999), although NDRG2 and NDRG3 expression is not under the
control of N-myc or c-myc (Boulkroun et al., 2002; Okuda and Kondoh,
1999). The encoded proteins of this family are highly conserved in
evolution. At the amino acid level, the four human NDRG4 members
share 53–65% identity. While primarily found in the cytoplasm, the
function of these proteins remains obscure with no obvious function
predicted from protein structure. Each member contains an α/β
hydrolase fold, which is common to a number of hydrolytic enzymes of
widely differing phylogenetic origin and catalytic function (Qu et al.,
2002). However, no hydrolytic catalytic site has been identiﬁed in this
family (Shaw et al., 2002).t 383 PRB/VUMC, Nashville, TN
35-A MRB IV/VUMC, Nashville,
ong),
l rights reserved.The existence of a gene family and its conservation through evo-
lution often implies the important functions of its members. To date,
studies of biological function have focused mainly on NDRG1 (also
known as ndr1, drg1, RTP/rit42, GRP78/BiP, Cap43, Proxy-1). Accumu-
lated data suggest that NDRG1 has at least two biological roles: it
attenuates cell proliferation and promotes differentiation and is
activated in response to various types of cell stress (Kokame et al.,
1996; Nishimoto et al., 2003; Zhou et al., 1998; rev in Kovacevic and
Richardson, 2006). Interestingly, a nonsense mutation in the human
NDRG1 gene is associated with hereditary motor and sensory neuro-
pathy-Lom (HMSNL) (Kalaydjieva et al., 2000). HMSNL is a severe
peripheral neuropathy characterized by Schwann cell dysfunction and
progressive axonal loss in the peripheral nervous system (Kyuno et al.,
2003). The importance of this nonsense mutation in disease causation
is underscored by the Schwann cell dysfunction phenotypes in Ndrg1
knockoutmice,which suggest that NDRG1 is essential formaintenance
of myelin sheaths in peripheral nerves (Okuda et al., 2004). Over-
expression of Ndrg1 in Xenopus laevis led to disrupted formation of the
pronephric ducts and reduced size of pronephric tubules and somite
disorganization, whereas Ndrg1 reduction bymorpholino resulted in a
failure of pronephric morphogenesis (Kyuno et al., 2003).
Much less is known about the functions of NDRG4 (also known as
smap8, Bdm1) and no previous studies have investigated its role in
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culture assays. NDRG4 protein has been shown to modulate activating
protein-1 (AP-1) activity and may regulate neurite outgrowth in NGF-
treated PC12 cells (Ohki et al., 2002). Most recently NDRG4 has been
reported to enhance NGF-induced ERK signaling components and
attenuates NGF-induced Elk-1 activation for transcription in PC12
cells, suggesting a possible role in neuronal differentiation (Hongo
et al., 2006). Others have suggested a role for NDRG4 in ampliﬁcation
of the PDGF induced mitogenic response of aortic smooth muscle via
the ERK signaling pathway in vitro (Nishimoto et al., 2003). However,
the in vivo function of NDRG4 has not been previously evaluated.
To investigate the developmental role of Ndrg4, we cloned ndrg4
from zebraﬁsh. We demonstrate that zebraﬁsh ndrg4 shows a highly
restricted pattern of expression in CNS and the developing heart from
24 h post-fertilization (hpf). We ﬁnd that reduction of ndrg4 by mor-
pholino antisense oligonucleotides attenuates myocardial prolifera-
tion and growth, and ultimately, limits heart function. Speciﬁcally, we
show that the loss of Ndrg4 function led to a signiﬁcant reduction of
myocardial cell number in both heart chambers due to lower cell
proliferation. In addition, we ﬁnd that Ndrg4 is required for regulating
versican and bmp4 expression levels correctly during the stages of
chamber formation. Interestingly, the heart defects in ndrg4morphant
embryos are similar to that of the tbx5 mutants (hst), including
dysregulated versican and bmp4 expression in the developing atrio-
ventricular canal of the heart (Garrity et al., 2002). Consistent with this
observation, we ﬁnd that ndrg4 expression in the developing heart is
attenuated by hst mutants and tbx5 morphants. Further, we observed
that tbx5 overexpression by tbx20 knock-down results in increased
expression of ndrg4 in the heart, suggesting that ndrg4 may be
downstream of tbx5 activation. This study provides the ﬁrst demon-
stration of the crucial role for Ndrg4 in heart development and may
shed new insight into the molecular mechanisms and genetic etiology
of Holt–Oram syndrome (Bruneau et al., 2001).
Materials and methods
Cloning of zebraﬁsh ndrg4
We ﬁrst predicted ndrg4 cDNA sequence according to mouse Ndrg4 cDNA, zebraﬁsh
htg data (AL772241166073 bp DNA HTG 26-SEP-2003 Danio rerio clone CH211-194M7,
WORKING DRAFT SEQUENCE, 4 unordered pieces) and EST database using Blast and
gene prediction tools (Gene ﬁnder, Genscan, GenomeScan, FGENESH). Following reverse
transcriptase PCR (RT-PCT) with the speciﬁc primers (5′-TTGCTTTCCTGCATCCGATTG-
CAA-3′ and 5′-GAGGTGAAGGCTAGAGGCAGCAAG-3′), we cloned the 1800 bp fragment
into pCRII-TOPO vector (Invitrogen). Sequencing of three individual clones revealed
identical, full-length cDNA sequence of zebraﬁsh ndrg4, which has been deposited in
GenBank with the accession number DQ649010.
Zebraﬁsh and microinjection
All zebraﬁsh and embryos were maintained at 28.5 °C and staged as previously
described (Kimmel et al., 1995). The tbx5 mutant hst was maintained by outcrossing to
standard wild-type lines (Garrity et al., 2002). Wild-type, transgenic Tg(cmlc2:gfp) (Shin et
al., 2005) or transgenic Tg(cmlc2:DsRed2-nuc) embryos (Mably et al., 2003) primarily at the
1-cell stage with chorion intact were injected with approximately 2 nl volume of mor-
pholino oligonucleotide, mRNA or DNA in Danieau buffer (Nasevicius and Ekker, 2000).
Morpholino antisense oligonucleotides were purchased from Gene-Tools (Corvallis,
OR). ndrg4-MO1 (5′-CCAGCACTCCGGCATGGTAGCTTAG-3′) was designed against the
ndrg4 translational start site. ndrg4-MO2 (TGCATTCATCTTACCCTTGAGGCAT) is a splice-
blocking MO, which targets the exon 3 and intron 3 splice junction of ndrg4 pre-mRNA.
We used two sets of control MOs: 1) Standard control MO (5′-CCTCTTACCTCAGTTA-
CAATTTATA-3′) and 5mis control MO, which is a 5 bp mismatch of ndrg4-MO2 (5′-
TGgATTgATCTTAgCCTTcAGGgAT-3′, lower case letters indicate altered bases). To test the
efﬁciency of the ndrg4-MO2, RT-PCR was performed using whole-embryo RNA from
∼30 embryos at 48 hpf, using the primers, P1 (5′-ATGCCGGAGTGCTGGGATGG-3′ and P2
(5′-AGCCCCAACTCCAATTCCGAC-3′) to detect the end ndrg4mRNA transcripts fromMO
treatment. The tbx5-MO 5′-GAAAGGTGTCTTCACTGTCCGCCAT-3′ (Garrity et al., 2002)
and the tbx20-MO 5′-CTCATGTGGAGAAGGGGTTTTGGAG-3′ (Szeto et al., 2002) have
been previously described.
To test the efﬁciency of the ndrg4-MO1, a transgenic construct driving expression of
an Ndrg4–EGYP fusion protein by the cmlc2 promoter was made (details available on
request). Brieﬂy, the cmlc2 minimal promoter (244 bp) was cut from pGEM-210/34
(Huang et al., 2003) and the EYFP fragmentwas isolated from pEYFP-N1 (BD BiosciencesClontech). The cmlc2–Ndrg4–EGYP DNA fragment was inserted into the pWhere
plasmid (InvivoGen) at the XhoI/NheI sites. Thus, H19 insulators ﬂanked this entire
fusionDNA fragment.15 pgof the linearized DNAwas injected intowild-type embryos at
1-cell stage with presence of ndrg4-MO1 or standard control MO.
For mRNA injection experiments, a 1029 bp PCR product (including initial codon
ATG and stop codon TGA) from adult zebraﬁsh heart cDNA with primers P1 and 5′-
CGCAAGGGTTCAGCAGGACACT-3′ was cloned into pCRII-TOPO (named pCRII-zNDRG4)
and then the ndrg4 insert was subcloned into pcGlobin2 (Ro et al., 2004) at EcoRI site.
To generate capped mRNA, plasmid was linearized by ClaI and transcribed with T7 RNA
polymerase using the mMESSAGE mMACHINE T7 in vitro transcription kit (Ambion)
according to the manufacturer’s instructions.
In situ hybridization
At 24 hpf, 0.2 mM 1-phenyl-2-thio-urea (Sigma, St Louis, MO) was added to embryo
media to prevent pigment formation. Embryos were collected at the appropriate stages
and ﬁxed in 4% paraformaldehyde (PFA), pH 7.0, in phosphate-buffered saline (PBS),
overnight at 4 °C. Fixed embryos were dechorionated, washed three times with PBS and
stored in methanol at −20 °C. Whole-mount in situ hybridization was performed using
digoxigenin labeled antisense RNA probe and visualized using anti-digoxigenin Fab frag-
ments conjugated with alkaline phosphatase (Roche Molecular Biochemicals). Ribop-
robesweremade fromDNA templates, whichwere linearized and transcribedwith either
SP6, T3 or T7 RNA polymerase. Embryos were processed and hybridized as described
(Thisse et al., 1993). The antisense RNA probes used in this study were tbx5 (Begemann
and Ingham, 2000), cardiac-myosin light chain-2 (cmlc2), ventricular myosin heavy chain
(vmhc) (Yelon et al., 1999), atrial myosin heavy chain (amhc), nppa (anf) (Berdougo et al.,
2003), versican (Walsh and Stainier, 2001), bmp4, gata4, Nkx2.5, hand2 (Yelon et al.,
2000), and ndrg4. To synthesize an ndrg4 antisense riboprobe, linearized pCRII-zNdrg4
(containing a 1029 bp fragment of zebraﬁsh ndrg4 cDNA) was used as a template.
Imaging, histology and morphometric analyses
For histology, embryos were ﬁxed overnight in 4% PFA in PBS at 4 °C and embedded
in JB-4 resin (Polysciences, Warrington, PA) according to manufacturer’s instructions
and sectioned at 5 μm, using an ultramicrotome. Serial sections were cut in transverse
orientation and stained with hematoxylin–eosin. For photography, living zebraﬁsh
embryos, plastic tissue sections and whole-mount in situ hybridized embryos were
photographed on an Axioplan microscope (Zeiss) using a digital camera (Dage).
Cardiomyocyte number and cell size in ndrg4-MO2 injected and control transgenic
embryos were measured as described (Mably et al., 2003; Jia et al., 2007). One Tg(cmlc2:
DsRed2-nuc) line (expressing RFP in cardiomyocyte nuclei) was used to measure
myocardial cell number at 48 hpf. The second Tg(cmlc2:gfp) line (expressing GFP
throughout the cardiomyocyte) was used to determinemyocardial cell size at 48 hpf and
myocyte number at 24 hpf. The Tg(cmlc2:DsRed2-nuc) line was not used for quantifying
myocyte number at 24 hpf because RFP positive cells are hardly detectable at the heart
tube stage (Mably et al., 2003). Brieﬂy, myocyte number in the atrium and ventricle was
determined by quantifying nuclei in 5 embryos fromeach group of ndrg4morphants and
control embryos. For clearly visualizing the margin of individual cell surface, embryos
were ﬂat mounted between two micro cover glasses and were subjected to confocal
imaging using 40× planapochromat of Zeiss LSM 510 confocal microscope system. Cell
sizes of 150 individual cardiomyocytes from each group of ndrg4morphants and control
embryos were measured using Image J. Numbers of cardiomyocytes from ﬂat-mounted
embryos at 24 hpf were counted in each confocal section using Pickpointer embedded in
the Image J. Pickpointer permits a single user-deﬁnedmark to appear through z stacks of
images, allowing the tracking of a single cell in overlapped z sections to avoid double
counting.
Analysis of cell proliferation
Cell proliferation in the zebraﬁsh heart was analyzed as previously described
(Ribeiro et al., 2007). Brieﬂy, the ndrg4-MO2 injected or control Tg(cmlc2:gfp) embryos
at 31 hpf or 48 hpf were injected with 2 nl 100mMBrdU in the pericardiac cavity region
of tricaine anesthetized embryos. These embryos were ﬁxed after 1 h incubation in
medium containing BrdU at 28.5 °C. The embryos were then treated with acetone for
10 min and digested in 0.25% trypsin in PBS without Mg2+ and Ca2+. Hydrochloric acid
(HCl) was used to treat the embryos for 1 h at room temperature. After extensive
washing, double whole-mount immunoﬂuorescence was performed using anti-BrdU
antibody (1:400, Invitrogen) and anti-GFP antibody (1:400, Invitrogen) as primary
antibodies, and goat anti-mouse Cy3 antibody (1:200, Invitrogen) and Alexa 488
donkey anti-rabbit antibody (1:200, Invitrogen) as secondary antibodies. The BrdU
labeled embryos were then stripped of their head, oriented in solidifying 0.5% agarose
and the heart region was confocal imaged using a Zeiss LSM510 microscope system.
Results
Cloning and sequence analysis of zebraﬁsh ndrg4
In order to investigate the potential function of Ndrg4 in zebraﬁsh
heart development, we cloned a single full-length cDNA of ndrg4 from
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capable of encoding a 339 amino acid polypeptide, a 101-bp 5′-UTR,
and a 679-bp 3′-UTR. Sequence analysis revealed that the amino acid
sequence of zebraﬁsh Ndrg4 protein shows a high degree of conserv-
ation (identities: 87%, positives: 94%) with mouse Ndrg4 (see Supple-
mental data). There is a typical α/β hydrolase fold as in other NDRG
proteins (Qu et al., 2002). Homology searches with the current zebra-
ﬁsh genomic database with the entire ndrg4 cDNA revealed one iden-
tical match on chromosome 25 (NC_007136.1) (data not shown), while
no other signiﬁcant alignment was observed with any other zebraﬁsh
genomic sequence. The zebraﬁsh ndrg4 gene includes 12 exons and
spans 26 kb.
Expression proﬁle of ndrg4 in early zebraﬁsh development
Whole mount in situ hybridization indicated an unexpected ex-
pression of ndrg4 in the developing zebraﬁsh heart. For comparison,
we used the pan-cardiac marker cmlc2 to identify cardiac tissues at
various stages. As we and others (Yelon et al., 1999; Yelon, 2001)
observed, cmlc2 is signiﬁcantly expressed in the bilateral cardiac pri-
mordia at the 14-somite stage (Fig. 1A) and in the cardiac cone at theFig. 1.Whole mount zebraﬁsh embryos processed for in situ hybridization using cmlc2
(A, C, E) or ndrg4 (B, D, F–M) speciﬁc anti-sense RNA probes. cmlc2 is expressed in the
bilateral cardiac primordia at the 14-somite stage (A), in the cardiac cone at the 21-
somite stage (C) and in the heart tube at the 24 hpf (E). The ﬁrst signiﬁcant indication of
ndrg4 cardiac expression occurs in the heart tube (arrow) at 24 hpf (F) and at 33 hpf (G).
ndrg4 is robustly expressed in both atrium and ventricle at 36 hpf (H), 48 hpf (I–L) and
72 hpf (M) with stronger signal in the ventricle. (J) Transverse section showing strong
expression of ndrg4 in the ventricle at 48 hpf. (L) Higher magniﬁcation of the indicated
heart region in panel K. (A–D) Dorsal views with anterior towards the top; (E–G, K, L)
lateral views; (H, I, M) frontal views with anterior towards the top. a, atrium; v,
ventricle. Arrow indicates heart or heart region.21-somite stage (Fig. 1C). At these stages, ndrg4 expression is marked
in the CNS but is almost undetectable in cardiac tissues (Figs. 1B, D).
However, by 24 hpf, ndrg4 expression resembles cmlc2 in occurring
uniformly throughout the heart tube (Figs. 1E, F). Subsequently, as the
heart tube undergoes loopingmorphogenesis, robust ndrg4 expression
continues throughout the heart with strong expression detected in the
ventricle (Figs. 1G–L). The expression of ndrg4 persisted in the heart at
72 hpf (Fig. 1M), the later embryonic period and the adult heart (RT-
PCR, data not shown). Thus, the temporally-regulated cardiac expres-
sion pattern suggests Ndrg4 is not required for early speciﬁcation of
cardiac progenitors, but may play a later role in chamber formation,
organ growth and remodeling.
Initially, ndrg4was expressed throughout CNS, from the 10-somite
through 14-somite stages (Figs. 1B and 2A). By the 21-somite stage, its
expression in CNS was restricted to the telencephalon, ventral dien-
cephalons and spinal chord (Fig. 2B). Subsequently (at 22–72 hpf),
expression was accentuated in cranial ganglia (trigeminal ganglion,
anterior lateral line ganglion and posterior lateral line ganglion),
hindbrain neuron cells, tegmentumand cerebellum (Figs. 2C–I). By 33–
72 hpf, prominent expression occurs in the retina but no expression
within the retinal proliferative zone (Fig. 2H).
Ndrg4 inhibition causes heart defects
To determine the role of Ndrg4 in zebraﬁsh development, we
designed two morpholino antisense oligonucleotides: 1) one to block
the translation of ndrg4 (ndrg4-MO1) and another to knockdown
Ndrg4 function by blocking RNA splicing (ndrg4-MO2). To test the
efﬁcacy of ndrg4-MO1, we developed a transgenic construct driving
expression of an Ndrg4–EYFP fusion protein under control of the cmlc2
promoter (Huang et al., 2003), which includes the hybridization ho-
mology region targetedbyndrg4-MO1. After injection of this linearized
DNA with 6.4 ng of control MO into 1-cell stage ﬁsh embryos, green
ﬂuorescent signal due to Ndrg4–EYFP expression in cardiomyocytes
was observed in 7.9% of injected embryos (n=108) at 48 hpf. By
contrast, injection of the Ndrg4–EYFP DNA in the presence of 6.4 ng of
ndrg4-MO1 resulted in the absence of EYFP expression in all injected
ﬁsh (n=155) (see Supplemental data). These experiments demonstrate
that ndrg4-MO1 is able to speciﬁcally block the translation of the ndrg4
gene.
To further demonstrate that the morphant phenotypes were the
result of speciﬁc loss of the ndrg4 gene function, we tested ndrg4-MO2,
which binds to the exon 3/intron 3 splice junction (Fig. 3A). Because
ndrg4-MO2 could result in either exon deletion or intron insertion in
ndrg4mRNA, we harvested embryos injectedwith sequential concent-
rations of morpholino and checked mRNA by RT-PCR with speciﬁc
primers as noted. As seen in Fig. 3B, gradual increase inMO2 resulted in
a progressive loss of exon 3 (121 bp). The 224 bp band was conﬁrmed
by sequencing to directly join exon 2 and exon 4 (Fig. 3C). Injection of
6.4 ng of MO2 resulted in complete exclusion of exon 3 from the ndrg4
mRNA in the injected embryos, resulting in a shift of the reading frame
and creation of an early stop codon. However, there was no inhibition
of ndrg4 splicing in embryos injected with 6.4 ng of a 5 bp mismatch
control ndrg4-MO. Thus, ndrg4-MO2 blocked the splicing of zebraﬁsh
ndrg4 in a dose-dependent and highly speciﬁc manner.
In our initial injection experiments, both morpholino oligonucleo-
tides caused the same phenotype at a range of 3.2 to 6.4 ng with
nonspeciﬁc effects observed at higher doses (data not shown). Since at
the same high concentration (N6.4 ng), MO2 was less toxic than MO1,
we usedMO2 in the following experiments. At 6.4 ng/embryo of ndrg4-
MO2, we consistently obtained morphants that had defects in the
hearts and heads (89%, n=180) but overall normal development.
Although the morphology of the initial heart tube of ndrg4morphants
at 24–33 hpf is indistinguishable from wild type, abnormal cardiac
development was visible in ndrg4-MO2 injected zebraﬁsh embryos
after 36-h development (data not shown). By 48 hpf and 3 days post-
Fig. 2. Expression of ndrg4 during zebraﬁsh nervous system development by whole mount in situ hybridization. (A) ndrg4was observed for the ﬁrst time in the CNS at the 10-somite
stage. (B) By 21-somites, ndrg4 is expressed in telencephalon, ventral diencephalon and spinal chord. (C–E) similar expression patterns of ndrg4 in CNS and sensory system at 22–
27 hpf. Expression of ndrg4 in nervous system is increased at 33 hpf (F), 48 hpf (G) and 72 hpf (I). (H) Transverse section at 48 hpf showing the strong signal in the retina of the eyes
with restriction of expression from the retina proliferative zone (rpz). (A, C–E,G) Dorsal views with anterior towards the left; (B, F, H), lateral views. allg, anterior lateral line ganglion;
ce, cerebellum; di, diencephalons; pllg, posterior lateral line ganglion; rm, rhombomeres; teg, tegmentum; tel, telencephalon; trg, trigeminal ganglion.
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edema, dilated atrium, looping defects, reduced circulation, and slower
heart rate with weaker contraction compared to their control siblings
(Figs. 4A–D; also see Movies 1 and 2 in Supplemental data). The heart
rate of ndrg4morphant embryos (101±38 beats/min, n=8) at 48 hpf is
75.1% of the control (135±27 beats/min, n=6). In addition, ndrg4mor-
phants also displayed defects in the development of their heads in-
cluding small eyes and prominent edema in the hindbrain. Thus, the
defects in the morphants are consistent with the expression pattern of
ndrg4. To demonstrate that these results were not due to an injection
artifact, we injected 1-cell embryos with a standard control MO or a 5
base-pair mismatch control MO of ndrg4 at a concentrations 10 ng/
embryo. This caused non-speciﬁc abnormalities distinct from the ty-Fig. 3. Validation of ndrg4-MO2 (knockdown by splice-blocking). (A) Schematic of the strat
used in the RT-PCR to test the efﬁciency of ndrg4 splice-blocking MO2 and the orange bar
embryos injected with 3.2–12.0 ng of the ndrg4-MO2. The ndrg4-MO2 efﬁciently blocks ndr
224 bp represent wildtype and exon3-deleted ndrg4 mRNA, respectively. (C) Sequencing ofpical defects seen in ndrg4 moprhants in less than 5% of the standard
control and 8% of the mismatch control embryos.
Another important criteria in determining the speciﬁcity of any
antisense approach is rescue of observed defects by expression of gene
speciﬁc RNA. Therefore, we simultaneously injected capped ndrg4
mRNA along with ndrg4-MO2. In rescue experiments, when 100 pg/
embryo of ndrg4 mRNA was injected with 6.4 ng ndrg4-MO2 into 1-
cell zebraﬁsh embryos, about 50% (78/156) of the injected embryos
displayed no or less severe cardiac defects at 48 hpf (Fig. 4E) compared
to that for ndrg4-MO2 only, in which 92% (228/248) of injected em-
bryos showed the typical cardiac phenotype described above. Injection
of ndrg4 mRNA (100 pg) alone did not induce heart defects. Thus, the
cardiac phenotype in ndrg4morphants could be ameliorated in aboutegy to target the exon3–intron3 boundary with ndrg4-MO2. Arrows represent primers
represents the ndrg4-MO2. (B) The RT-PCR was performed on wild-type embryos and
g4 mRNA splicing by exon3 deletion in a dose-dependent manner. Bands of 345 bp and
the 224 bp band reveals direct connection of exon 2 and exon 4.
Fig. 4. ndrg4 morphant phenotypes. Lateral views at 48 hpf. (A, B) The overall morphology of an uninjected (A) and ndrg4-MO2-injected (B) embryos. Compared to its sibling (C),
ndrg4-MO2 injected embryo (D) displays pericardial edema, dilated atrium, unlooped, stretched heart and head defects (smaller eyes and prominent edema in the hindbrain). (E) Co-
injection of ndrg4 mRNA with ndrg4-MO2 signiﬁcantly rescued the cardiac, eye and brain phenotype induced by ndrg4 inhibition.
490 X. Qu et al. / Developmental Biology 317 (2008) 486–49645.5% of the co-injected embryos. The eye size and head defects in MO
injected embryos was also partially rescued by mRNA injection (Fig.
4E). Therefore, we conclude that the speciﬁc morphant phenotypes
produced by ndrg4-MO2 result primarily from the selective inhibition
of Ndrg4.
Defective cardiac looping in ndrg4 morphants
As described above, one of the prominent morphological defects in
the ndrg4 morphant heart is failure to complete looping. To furtherFig. 5. Attenuation of Ndrg4 results in early looping abnormalities. The cmlc2-driven GFP is ex
(E–H), compared to the clearly looped heart of uninjected Tg(cmlc2:gfp) embryos (A, C, E, G), t
(A, B, E, F), Lateral views with anterior towards the left; (C, D, G, H), frontal views with antedeﬁne abnormalities in looping of the heart, we injected transgenic Tg
(cmlc2:gfp) embryos with ndrg4-MO2 and evaluated heart looping at
sequential stages of development. At 36 hpf, the heart tube of control
zebraﬁsh embryos loops to the right, whereas the heart tube in ndrg4
morphants remains central and linear in a tubular structure (data not
shown). By 48 hpf and 3 dpf, there was no obvious perturbation in
cmlc2-driven GFP expression in ndrg4 morphants when compared to
the control, but there was an obvious defect in looping as the heart
continued to retain its linear conﬁguration, midline orientation, and
circulation was depressed (Fig. 5). In histological sections of ndrg4-pressed in cardiomyocytes of transgenic Tg(cmlc2:gfp) embryos. At 2 dpf (A–D) and 3 dpf
he heart of ndrg4morphant (B, D, F, H) remained central and linear in a tubular structure.
rior towards the top. a, atrium; v, ventricle.
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3 dpf, the overall size of ventricle and atrium was markedly smaller
than age-matched controls (Figs. 6A, B). In addition, sections showed
that regions of local cell proliferation around the outﬂow tract and
atrioventricular (AV) junction were less extensive in morphants than
wild-type. The extracellular matrix between myocardium and endo-
cardium in the atrium was enlarged compared to age-matched wild-
type embryos.
Attenuation of Ndrg4 results in reduced myocyte number and cell size
The smaller overall size of the cardiac chambers in ndrg4 morõ-
phants suggests a possible primary defect in proliferation and/or size
of cardiomyocytes. To address this question directly, we determined
myocyte cell number and size using confocalmicroscopic analysis after
injection of the transgenic Tg(cmlc2:DsRed2-nuc) and Tg(cmlc2:gfp)Fig. 6. Attenuation of Ndrg4 results in smaller cardiac chambers and a reduction in the numb
heart. Outﬂow tract (blue arrows), AV junction (black arrows) and the enlarged space (arrow
only a few blood cells in the MO treated heart. Confocal images of the heart of control (C) and
numbers of cardiomyocytes in un-injected and ndrg4-MO2 injected embryos at 2 dpf (Data
Confocal images of the heart of control (F) and ndrg4-MO2 injected (G) Tg(cmlc2:gfp) embryos
embryos at 2 dpf. Therewas no change inmyocardial cell number between control (I) and ndr
cells in the heart: 182±16 vs. 177±12, respectively (Data are from 5 embryos for each groupembryos with ndrg4-MO2. We decided to quantify cell number at
48 hpf, the earliest stage in which cardiac morphology was overtly
different fromwild-type. As shown in Figs. 6C–E, ndrg4-MO2 injected
Tg(cmlc2:gfp) embryos at 2 dpf showed a signiﬁcant reduction in the
number of cardiomyocytes in both chambers (atria and ventricle)
when compared to controls: myocyte number in atrium and ventricle
of injected ﬁsh was reduced by 36.1% (97±11 vs. 62±6) and 18.5%
(173±11 vs. 141±14) respectively (Fig. 6E). To determine the potential
effect of Ndrg4 inhibition on myocyte size, we treated Tg(cmlc2:gfp)
embryos with ndrg4-MO2 and measured their cell size at 48 hpf with
confocal imaging. We found only a slight reduction (10.3%) in myocyte
size (area) in ndrg4 morphants in comparison with control (193.2±
8.5 μM2 vs. 215.3±4.5 μM2, PN 0.05) (Figs. 6F–H).
We questioned whether the number of cardiomyocytes in ndrg4
morphants was decreased at even earlier stages and thus reduction in
the myocyte number at 48 hpf might reﬂect a decrease in initial myo-er of cardiomyocytes. Transverse sections of 3 dpf wild-type (A) and ndrg4morphant (B)
heads) between myocardium and endocardium in the dilated atrium are indicated. Note
ndrg4-MO2 injected (D) Tg(cmlc2:DsRed2-nuc) embryos at 2 dpf. (E) Comparison of the
are from 5 control and 5 injected embryos and are expressed as means±S.D. *Pb0.05).
at 2 dpf. (H) Comparison of the size of cardiomyocytes in control and ndrg4-MO2 injected
g4-MO2 (J) injected Tg(cmlc2:gfp) embryos at 24 hpf based on the number of GFP positive
and are expressed as means±S.D.) a, atrium; v, ventricle; control, mismatch-MO.
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ndrg4-MO2 and measured myocyte number in control and morphant
embryos at 24 hpf. We found no attenuation in myocardial cell number
between control (182±16; n=5; Fig. 6I) and ndrg4-MO2 (177±12; n=5;
Fig. 6J) injected Tg(cmlc2:gfp) embryos based on the number of GFP
positive cells in the heart tube. Thus, we conclude that attenuation of
Ndrg4 did not result in a decrease in early myocyte differentiation.
Ndrg4 reduction attenuates cardiomyocyte cell proliferation
The reduced myocyte number in ndrg4morphants prompted us to
investigate myocyte cell proliferation and apoptosis during 1–2 dpf. At
33 hpf or 48 hpf, there was not a signiﬁcant number of apoptotic cells
observed in the heart of control or ndrg4-MO2 treated embryos by
TUNEL assay, although there was a clear increase in apoptosis within
the developing CNS in ndrg4-MO2 treated embryos at 48 hpf (data not
shown). To determine myocyte proliferation in the early developing
heart we gave a one-hour pulse of BrdU by injecting a BrdU solution in
the pericardiac cavity (Ribeiro et al., 2007). As shown in Fig. 7, at 31 hpf
the number of BrdU positive cells in ndrg4-MO2 treated embryonic
heart (21.0±3.0; n=5) is comparable to control (23.1±3.5; n=5). This
result is consistent with the normal heart development of ndrg4mor-
phants at this stage. However, at 48 hpf ndrg4-MO2 injected embryos
(15.8±2.9; n=5) display lower number of proliferating cells than
control (35.1±5.3; n=5) in the developing heart. Because, the total
number of cardiomyocytes (Fig. 6) in ndrg4 morphants (203±9) at
48 hpf is lower than control (260±11), we calculated the proliferation
index (the average of the total number of BrdU positive cells per 100
cardiomyocytes). Hearts of ndrg4 morphants at 48 hpf had a signi-
ﬁcantly lower proliferative index than control embryos (7.8±2.1 vs.
13.5±3.9; Pb0.01). Therefore, attenuation of Ndrg4 resulted in a de-
crease in both myocyte proliferation and myocyte cell number at
48 hpf that was not detected during early cardiac development at
24 hpf. Taken together, these data indicate an essential requirement
for Ndrg4 in regulation of myocardial proliferation and cardiac growth
during early cardiogenesis suggesting that cell growth and cell
division are tightly coupled in the embryonic heart.
Normal cardiac chamber formation but abnormal AV canal
differentiation in ndrg4 morphants
ndrg4 morphants formed an overtly normal heart tube, despite
expression of ndrg4 in the heart already at this stage. Moreover, atFig. 7. Attenuation of Ndrg4 induces a reduction in cell proliferation of the cardiomyocytes. Al
and ndrg4-MO2 treated (B) embryonic hearts at 31 hpf has been detected, ndrg4-MO2 injecte
48 hpf. All images represent reconstructions of confocal Z-stack sections imaged on who
proliferation index (the average of the total number of BrdUpositive cells in per 100 cardiomy24 hpf, expression of cmlc2, nkx2.5, hand2 and gata4 in the developing
heart tube of ndrg4-MO2 injected embryos was indistinguishable from
un-injected embryos (Figs. 8A, B and data not shown). By 33 hpf, ndrg4
morphants also showed normal expression of tbx5, nppa and cmlc2
(Figs. 8C–H), indicating that myocardial differentiation proceeded
normally in ndrg4-morphant embryos. To examine cardiac chamber
formation in ndrg4morphants, we analyzed the expression of two pan-
cardiac markers cmlc2 and nppa, as well as the ventricular marker
vmhc (Yelon et al., 1999), and the atrial marker amhc (Berdougo et al.,
2003). We detected no abnormalities in the expression levels of these
chamber speciﬁc molecular in the ndrg4MO knockdown embryos (Fig.
8). These data suggest that atrial and ventricular speciﬁcation occurred
normally in ndrg4-MO2 injected embryos.
To investigate whether cardiomyocytes are properly differentiated,
we analyzed two genes (versican and bmp4) which are initially ex-
pressed broadly in thewild-type ventricle but later (by 48 hpf) become
highly restricted to the AV junction (Walsh and Stainier, 2001). In
contrast to wild-type (Fig. 8O), ndrg4-MO2 injected embryos (41 of 46
morphants examined at 48 hfp) showed dispersed expression of ver-
sican throughout the ventricle, similar towhat is ordinarily observed in
33 hpf wild-type hearts (Fig. 8P). In contrast, the punctate expression
of versican in the otoliths is characteristic of embryos at 48 hpf (Garrity
et al., 2002), and indicates that morphants are not subject to a general
developmental delay. Similarly, bmp4marked the developing AV canal
in 48 hpf wild-type zebraﬁsh embryos (Fig. 8S), whereas ndrg4-MO2
treated embryos (Fig. 8T) showed diffusely distributed bmp4 in the AV
canal and ventricular regions. Thus, ndrg4 appears to be required for
molecular patterning of the atrio-ventricular canal.
Regulation of ndrg4 by Tbx5
The phenotype of our ndrg4morphants was remarkably similar to
that described for the hst mutants (normal myocyte speciﬁcation, ab-
normal looping, weak contractility, abnormal restriction of versican
and bmp4 expression) which lacks functional Tbx5 (Garrity et al.,
2002). In addition, expression of tbx5 (Begemann and Ingham, 2000)
precedes the expression of ndrg4 in the heart ﬁeld. Because tbx5 is a
key transcription factor that regulates cardiac morphogenesis and
gene expressionwithin the developing heart (Basson et al., 1999; Horb
and Thomsen, 1999; Bruneau et al., 2001; Garrity et al., 2002), we
wished to determine the relationship between ndrg4 and tbx5 in re-
gulation of versican and bmp4 in heart. We ﬁrst injected wild type 1-
cell embryos with tbx5-MO and checked ndrg4 expressionwith wholethough no signiﬁcant difference in the number of BrdUpositive cells between control (A)
d embryos (D) display lower number of proliferating cells than control (C) in the heart at
le hearts. Green, anti-GFP antibody; Red, anti-BrdU antibody. (E) Histogram showing
ocytes) in the heart of 48 hpf embryos: control,13.5±3.9; ndrg4-MO2, 7.8±2.1 (*Pb0.01).
Fig. 8. Effect of ndrg4 knock-down on cardiac gene expression. At 24 hpf and at 33 hpf heart tube, no alternationwas detected in cmlc2 (A, B, E, F), tbx5 (C, D) or nppa (G, H) expression
level between wild-type (A, C, E, G) and ndrg4morphants (B, D, F, H) with whole mount in situ hybridization. Note normal jogging out in the heart of morphants. At 48 hpf heart, no
change was observed in vmhc (I, J), cmlc2 (M, N), amhc (Q, R) and nppa (K, L) expression level betweenwild-type (I, K, M, O, Q, S) and ndrg4morphant (J, L, N, P, R, T). nppa and cmlc2
are expressed throughout the heart, vmhc is expressed in the ventricle and amhc is expressed in the atrium. Note the unlooped heart of ndrg4 morphant (N). At 48 hpf, versican is
expressed at the boundary of the atrium and the ventricle (arrow) in wild type embryos (O), but is expressed throughout ndrg4 morphrant hearts (P). bmp4 expression is also
prominent in the myocardial region of AV junction (between the arrows) in 48 hpf wild type zebraﬁsh embryos (S), whereas ndrg4-MO2 injection resulted in strong ectopic
expression of bmp4, especially in the ventricular region (T, arrowhead). (A, B) Dorsal views with head towards the top; (C–H), Lateral views with anterior towards the left; (I–T),
frontal views with anterior towards the top.
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we observed that ndrg4 expression in the embryonic heart was
signiﬁcantly decreased (Figs. 9B, E), with no change in ndrg4
expression in the CNS and sensory system where ndrg4, but not
tbx5, is expressed (data not shown). We then examined ndrg4 expres-
sion in hst embryos to conﬁrm this effect of loss of Tbx5 function. As
can be seen in Fig. 9, at 35 hpf and 48 hpf, there appears to be amarked
attenuation of ndrg4 expression in the heart of hst mutant embryos.
Since tbx5 expression is down regulated by Tbx20 in early deve-
lopment of the zebraﬁsh heart (Szeto et al., 2002), we injected wild-
type embryos with tbx20-MO to induce tbx5 overexpression. As shown
in Fig. 10, consistent with the previous report (Szeto et al., 2002), tbx5
expression in tbx20-MO injected embryos at 33 hpf or at 48 hpf issigniﬁcantly higher than control. As we expected, compared to control
embryos, ndrg4 expression in tbx20 morphants is correspondingly
increased at 33 hpf or at 48 hpf. These data are consistent with the
hypothesis that Tbx5 acts to regulate the levels of ndrg4 expression
during heart development and suggest that ndrg4 may be a down-
stream target of tbx5 activation.
Discussion
ndrg4 is conserved and expressed during cardiac development
We have cloned and characterized ndrg4, a novel member of the
ndrg family from zebraﬁsh. Homology analysis reveals that the NDRG4
Fig. 9. ndrg4 is down regulated by Tbx5 attenuation. At 35 hpf (A–C) and 48 hpf (D–F),
compared with uninjected (A, D) embryos, ndrg4 expression (whole mount in situ
hybridization) in tbx5-MO injected (B, E) or hstmutant (C, F) embryos was dramatically
decreased. Arrow indicates heart region. a, atrium; v, ventricle. All are frontal views
with anterior towards the top.
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spatial and temporal regulation conﬁnes the ndrg4 expression to the
forming heart and nervous system. Speciﬁcally, ndrg4 is expressed in
the developing heart from 24 hpf with increased expression in the
later period and in the adult heart (XQu and HSB, unpublished). Once
the heart tube is formed, several key cardiogenic events occur in rapid
succession (Stainier et al., 1993; Stainier, 2001), including looping
morphogenesis by 30 hpf, delineation of visibly distinct atrial and
ventricular chambers by approximately 36 hpf, formation of the
cardiac cushions, or AV valve analogue at approximately 48 hpf, and
myocardial proliferative growth from 48 hpf. Thus, ndrg4 is expressed
during the later critical stages of cardiac morphogenesis and proli-
ferative growth (Srivastava and Olson, 2000; Yelon et al., 1999;
Stainier, 2001). Interestingly, in mouse, unlike the rather ubiquitous
expression of Ndrg1–3, Ndrg4 is expressed predominantly in the myo-Fig. 10. ndrg4 is up regulated by Tbx5 augmentation via tbx20-MO. Compared to uninjected e
views with anterior towards the left) and 48 hpf (E–H; frontal views with anterior toward
ventricle of heart.cardium of the developing heart and CNSwith increased expression in
the postnatal period and the adult (Okuda and Kondoh,1999; Qu et al.,
2002; and data not shown). The conservation of ndrg4 gene
expression in the developing hearts may suggest an evolutionarily
conserved function as well.
Abnormal cardiac defects in ndrg4 morphants
Prior to the onset of cardiac looping, cardiogenesis progresses nor-
mally in ndrg4 morphants, indicating that there is no essential
requirement for Ndrg4 function in the very early stages of heart
development. Although the dysmorphic hearts in thendrg4morphants
appeared to form two distinct chambers, the heart remained as a linear
tube and did not form the characteristically looped structure, resulting
in a weakly contractile heart with a slower rhythm.
Reduction of Ndrg4 results in a signiﬁcant decreased number of
cardiomyocytes by 48 hpf. Because ndrg4 is not expressed during early
myocardial differentiation from the mesoderm, the reduction in
myocyte number is unlikely to result from a defect in cardiomyocyte
commitment. The normal expression of cardiac markers cmlc2, nppa
and tbx5 at 33–48 hpf indicates that a degree of myocardial differ-
entiation and chamber maturation does occur in ndrg4 morphants,
although continued differentiation is compromised and heart function
deteriorates with time.
While we found no signiﬁcant changes in apoptosis at these early
stages ofmyocardial development,wewere able to detect a decrease in
myocardial cell number at 48 hpf. In addition, we documented that at
48 hpf ndrg4-MO2 injected embryos display signiﬁcantly lower num-
ber of proliferating cells than control in the heart, although the number
of BrdU positive cells in ndrg4-MO2 treated embryonic heart at 31 hpf
is indistinguishable from control. Consistently, ndrg4 expression in
zebraﬁsh heart is not signiﬁcant before 24 hpf and abnormal cardiac
development in ndrg4-MO2 injected zebraﬁsh embryos was only
visible after 36 hpf. Therefore, the decrease in myocyte number in
ndrg4morphants is primarily due to the reducedmyocyte proliferation
suggesting that Ndrg4 is required for maintenance of normal cell
proliferation after formation of the heart tube.
Of note, expression of NDRG2, which is most closely related to
NDRG4, as well as NDRG1, has been documented to reduce cell growth
in vitro (Kurdistani et al., 1998; Guan et al., 2000; Deng et al., 2003).mbryos, tbx5 and ndrg4 expression in tbx20-MO injected embryos at 33 hpf (A–D; lateral
s the top) was signiﬁcantly increased. Arrow indicates heart and arrowhead indicates
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microtubules in centrosomes and to participate in the spindle check-
point (Kim et al., 2004). Interestingly, NDRG4 may regulate neural cell
proliferation and differentiation via the Ras-ERK pathway (Ohki et al.,
2002; Hongo et al., 2006). The human NDRG4 (smap8) was suggested
to play a role in PDGF-induced mitogenesis of a rat aortic smooth
muscle cell line by ampliﬁcation of the ERK (extracellular signal-
regulated kinase) signal (Nishimoto et al., 2003). Therefore, these data
from cell culture assays are consistent with our in vivo data suggesting
a potential role of Ndrg4 in proliferation. It is noteworthy that ver-
tebrate NDRG4 shows high of amino acid sequence conservation (56%)
to DrosophilaMESK2 (misexpression suppressor of dominant-negative
KSR, kinase suppressor of Ras), a gene product which may represent a
new component of the Ras pathway or of other signaling pathways
that can modulate signaling by Ras (Huang and Rubin, 2000). The
involvement of the Ras pathway in heart development has been well
documented. Ras is implicated in hypertrophic growth of the myo-
cardium (Clerk and Sugden, 2000; Sugden, 2003) and in valve form-
ation (Lakkis and Epstein, 1998; rev in Yutzey et al., 2005). Thus, it is
tempting to speculate that Ndrg4 might regulate heart development
via Ras pathway but clearly further investigation is warranted.
ndrg4 is downstream of tbx5
The T-box transcription factor tbx5 has emerged as a key gene
regulating heart development from amphibians to mammals (Horb
and Thomsen, 1999; Liberatore et al., 2000; Bruneau et al., 2001).
Mutations in human TBX5 are the cause of Holt–Oram syndrome, a
haploinsufﬁcient syndrome characterized by heart and forelimb
defects (Basson et al., 1999; Li et al., 1997), and dominant negative
interference of Xenopus tbx5 leads to near-total absence of differ-
entiated heart tissue and early cardiac markers (Horb and Thomsen,
1999). Similar defects have been found in mice lacking one copy of the
Tbx5 gene (Bruneau et al., 2001). Mice lacking both copies of Tbx5 have
more severe defects, including an absence of heart looping and
alterations in a subset of cardiac-speciﬁc genes, although the early
steps in cardiac development appear normal (Bruneau et al., 2001).
We were impressed that loss-of-function of Ndrg4 by MO knock-
down in zebraﬁsh closely phenocopies the cardiac defects in hst
mutant embryos (tbx5 mutants). Although tbx5 is expressed in the
developing heart earlier (Begemann and Ingham, 2000) than ndrg4,
the heart of hst mutant embryos appears to form and function nor-
mally through the early heart tube stage, manifesting only a slight
bradycardia compared with wild-type siblings (Garrity et al., 2002).
The predominant cardiac defects of hst mutant embryos become evi-
dent well after the development of discrete morphological chambers
and after the onset of circulation. The heart fails to loop and then
progressively deteriorates, a process affecting the ventricle as well as
the atrium.
An intriguing observation in this study is that ndrg4 expression is
speciﬁcally reduced in the hearts of tbx5mutants or morphants while
ndrg4 expression in other regions of mutant embryos are unaffected. It
has been reported that other cardiac markers (nkx2.5, hand2, bmp4,
cmlc2 and vhmc) are normal in hst mutant embryos at the 15-somite
stage. Both vmhc and amhc are expressed normally in the heart in hst
mutant embryos at 26 and 48 hpf (before and after overt chamber
formation). These data suggest that atrial and ventricular fates are
assigned properly in hstmutant embryos (Garrity et al., 2002). There-
fore, reduction of ndrg4 expression in tbx5 mutant hearts is not just
due to a general myocardial differentiation defect in tbx5 mutant
myocardium. Moreover, attenuation of either Tbx5 or Ndrg4 resulted
in abnormal upregulation of versican and bmp4 in zebraﬁsh heart at
2 dpf. Unfortunately, multiple attempts at tbx5 mRNA injection
resulted in severe embryonic toxicity or lethality preventing analysis
of subsequent alterations in the expression of Ndrg4. However, tbx5
expression is down-regulated by Tbx20 in early development zeb-raﬁsh heart (Szeto et al., 2002), therefore we investigated if tbx5 over-
expression in heart by Tbx20 reduction could induce ndrg4 expres-
sion. Indeed, we observed that ndrg4 expression in tbx20 morphant
heart is increased at 33 hpf or at 48 hpf. These data further suggest
that Tbx5 acts to regulate the level of ndrg4 expression during the
heart development, and that ndrg4 is potentially a novel downstream
target of tbx5 activation and may be at least partially responsible for
the defects observed in hearts of tbx5 null mutant animals. Since Tbx5
is not expressed in the CNS, ndrg4 regulation in neural tissues pre-
sumably occurs by alternative mechanisms.
To date, only a few cardiac speciﬁc genes have been identiﬁed as
Tbx5 target genes (Plageman and Yutzey, 2005; Stennard and Harvey,
2005) while a myriad of genes have been recently identiﬁed bymicro-
array analysis to be affected by alteration in Tbx5 dosage (Mori et al.,
2006; Plageman and Yutzey, 2006). Interestingly, Ndrg4 has not been
identiﬁed as a downstream target in any of these previous studies. As
the mechanism by which TBX5 haploinsufﬁciency causes cardiac
abnormalities seen in Holt–Oram syndrome is still not well under-
stood, it will be of great interest to determine if there is a genetic link
between NDRG4 gene and congenital heart disease. The observation
that NDRG4 expression is induced by homocysteine (Nishimoto et al.,
2003) leads to further speculation that it might be involved in the
increased incidence of congenital heart disease in offspring of mothers
withdefects in homcysteinemetabolism (Bootet al., 2003;Hobbs et al.,
2005).
In summary, this study is the ﬁrst to demonstrate a role for ndrg4 in
cardiac development and provides the ﬁrst functional study of Ndrg4
in a vertebrate animal species. While not required for myocardial spe-
ciﬁcation and early differentiation, ndrg4 appears to play an important
role in regulating myocyte cell proliferation and is required for normal
cardiac development in the ﬁsh. Further delineation of its potential
role in downstreammediation of Tbx5 signal transduction and its role
in atrioventricular canal morphogenesis will be the subject of con-
tinuing investigation.
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